Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450944 · ClinicalTrials.gov registry record · Phase 1
Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00450944 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT00450944, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Immunotoxins, such as anti-CD19 and anti-CD22, can find cancer cells that express CD19 and CD22 and kill them without harming normal cells. This may be an effective treatment for B-cell acute lymphoblastic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of anti-CD19 and anti-CD22 immunotoxins in treating patients with refractory or relapsed B-cell acute lymphoblastic leukemia.
Interventions
- BIOLOGICAL deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-02-22 |
| Est. Completion | 2010-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450944
The ClinicalTrials.gov registry entry for NCT00450944 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins is the first listed.
NCT00450944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450944 about?
NCT00450944 is a clinical study titled "Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia". RATIONALE: Immunotoxins, such as anti-CD19 and anti-CD22, can find cancer cells that express CD19 and CD22 and kill them without harming normal cells. This may be an effective treatment for B-cell acute lymphoblastic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose o...
What is the current status of trial NCT00450944?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2006-02-22. Estimated completion is 2010-04-01.
What interventions are being tested in trial NCT00450944?
The interventions under investigation include: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins (BIOLOGICAL).
Who is sponsoring clinical trial NCT00450944?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.